Centre for Virology, UCL Medical School, London, UK.
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.
In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging-providing evidence of a reduction in the incidence of HCMV viraemia-they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.
在这篇综述文章中，我们考虑了一些表明可以减少人类巨细胞病毒（HCMV）从供体向免疫幼稚个体传播的研究结果。最近进行了两项随机对照试验，一项是在移植前对受者进行主动免疫，另一项是在移植时使用针对 HCMV 的单克隆抗体进行被动免疫。尽管现有数据令人鼓舞——提供了 HCMV 病毒血症发生率降低的证据——但它们还不足以证明已经完全防止了传播。在这里，我们反思了这些研究，并提出了一套 5 条标准，如果在未来得到满足，可以被视为主动和/或被动免疫针对 HCMV 可有效阻断病毒从供体传播的证据。我们建议在设计未来的随机对照试验时考虑这些标准。
